This episode reviews a 2026 study investigating whether a modified-live Mycoplasma bovis vaccine can help protect young calves from one of the most frustrating respiratory disease pathogens in the cattle industry. The researchers conducted a controlled challenge trial in neonatal calves, comparing vaccinated and non-vaccinated groups after exposure to Mycoplasma bovis.
The results showed several encouraging outcomes for vaccinated calves. They experienced fewer lung lesions, fewer days with fever, and a shorter duration of clinical illness compared with non-vaccinated controls. In addition, vaccinated calves developed higher antibody levels both before and after challenge, suggesting that the vaccine stimulated a meaningful immune response.
The discussion also highlights important statistical considerations. While the study found positive effects on lung lesions and fever duration, some clinical disease measures showed less dramatic differences, emphasizing the need to carefully interpret challenge-study data. The hosts point out that challenge trials measure vaccine efficacy under controlled conditions, which differs from vaccine effectiveness in real-world ranch environments.
Another key point is that the study was funded and conducted by researchers affiliated with the vaccine manufacturer, making critical evaluation of study design and interpretation especially important. Despite those limitations, the trial was well designed, with randomization, blinding, and strong biosecurity controls. Overall, the paper provides promising evidence that a modified-live Mycoplasma bovis vaccine may become a useful tool for respiratory disease management, while also underscoring the need for larger field studies to determine how well those results translate to commercial cattle operations.
Podcast (bovine-science-with-bci): Play in new window | Download